These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
980 related articles for article (PubMed ID: 28534250)
1. Advancing Immunotherapy in Metastatic Breast Cancer. Mansour M; Teo ZL; Luen SJ; Loi S Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Luen SJ; Savas P; Fox SB; Salgado R; Loi S Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579 [TBL] [Abstract][Full Text] [Related]
4. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974 [TBL] [Abstract][Full Text] [Related]
6. Emerging Opportunities and Challenges in Cancer Immunotherapy. Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738 [TBL] [Abstract][Full Text] [Related]
7. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Hu ZI; Ho AY; McArthur HL Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Ghatalia P; Zibelman M; Geynisman DM; Plimack ER Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of breast cancer. Ernst B; Anderson KS Curr Oncol Rep; 2015 Feb; 17(2):5. PubMed ID: 25677118 [TBL] [Abstract][Full Text] [Related]
10. Rationale for immunological approaches to breast cancer therapy. Monnot GC; Romero P Breast; 2018 Feb; 37():187-195. PubMed ID: 28629632 [TBL] [Abstract][Full Text] [Related]
11. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related]
12. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130 [TBL] [Abstract][Full Text] [Related]
13. Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. Force J; Leal JHS; McArthur HL Curr Treat Options Oncol; 2019 Mar; 20(4):35. PubMed ID: 30923913 [TBL] [Abstract][Full Text] [Related]
14. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Gide TN; Wilmott JS; Scolyer RA; Long GV Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120 [TBL] [Abstract][Full Text] [Related]
15. An Expanding Role for Immunotherapy in Colorectal Cancer. Bever KM; Le DT J Natl Compr Canc Netw; 2017 Mar; 15(3):401-410. PubMed ID: 28275038 [TBL] [Abstract][Full Text] [Related]
16. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R Front Immunol; 2021; 12():775761. PubMed ID: 34925348 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Bertucci F; Gonçalves A Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073 [TBL] [Abstract][Full Text] [Related]
18. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722 [TBL] [Abstract][Full Text] [Related]
19. Ovarian Cancer Immunotherapy: Turning up the Heat. Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030 [TBL] [Abstract][Full Text] [Related]
20. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma. Podar K; Jager D Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]